Danish pharma giant Novo to use Anthropic's Claude to advance AI drug discovery

Novo has agreed to deploy Anthropic’s Claude, a generative AI large language model, to accelerate its drug-discovery efforts by integrating advanced AI into research workflows. The move centers on using Claude’s capabilities to process and synthesize biomedical literature, analyze experimental and clinical data, generate hypotheses, and assist in the design and prioritization of candidate molecules - all intended to speed target identification, shorten development timelines and reduce R&D costs. The collaboration positions Claude as an embedded research tool for scientists to surface insights faster and iterate more rapidly across preclinical discovery stages.

The deal reflects a broader shift as major pharmaceutical companies form strategic partnerships with AI providers to industrialize model-assisted discovery and compete on computational advantage. It also sharpens attention on data governance, model safety and intellectual-property boundaries, since integrating sensitive biomedical datasets into third-party models requires strict security, validation and regulatory oversight. If successfully validated in practice, the deployment promises to reshape how early-stage research is conducted, increasing throughput and hypothesis generation while demanding rigorous experimental follow-up and compliance with clinical-development standards.